Palisade Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Carlsbad, CA, Sept. 23, 2022 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq:PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that it had made equity grants to two new employees under its 2021 Inducement Plan.
Related news for (PALI)
- Cancer Breakthroughs, Blockchain Bets, and Biotech Boldness
- Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108
- 24/7 Market News Snapshot 07 August, 2025 – Palisade Bio, Inc. Common Stock (NASDAQ:PALI)
- Don’t Miss Out: MoBot’s Latest Stock Updates 07/23/25 09:00 AM
- Today’s Top Performers: MoBot’s Market Review 07/21/25 05:00 PM